Transforming a-Synucleinopathy Diagnosis and Treatment
QABY Biotech develops coordinated diagnostic and therapeutic platforms designed to identify disease-driving α-synuclein biology and translate it into targeted clinical interventions.
Early Detection
Our assays detect multiple pathological forms and post-translational modifications (PTMs) of α-synuclein across CSF and peripheral biofluids, supporting early and accurate characterisation of synucleinopathies.
Targeted Therapeutic Solutions
Our therapeutic program focus on selectively neutralising disease-associated α-synuclein species, aiming to protect neurons and modify disease course.
Theranostic Precision Care
By linking biomarker readouts with therapeutic design, QABY’s approach supports patient selection, treatment matching, and monitoring, enabling a unified pathway toward precision care.
Our Story
QABY Biotech was founded on more than three decades of world-leading synucleinopathy research, driven by a mission to bring meaningful diagnostic and therapeutic solutions to patients worldwide. As Qatar’s first healthcare biotech company, we combine scientific depth, regional leadership, and global vision to reshape what is possible in neurodegenerative disease care.
Built on 20+ Years of Scientific Leadership
Our foundation comes from decades of pioneering work in synucleinopathies, with deep expertise in α-synuclein biomarkers, assay development, and translational neuroscience. This experience informs QABY’s platforms, partnerships, and strategic direction.
Rooted in Qatar, Built for Global Impact
As a Qatar-based biotech company, QABY contributes to the country’s growing scientific landscape while developing platforms with global relevance. Our goal is to bring precision diagnostics and therapeutics in synucleinopathies to patients who need them most, wherever they are.
A Team United by Purpose and Innovation
From bench to bedside, our team brings together scientific excellence, translational experience, and a shared commitment to improving patient lives. Our work is driven not just by data, but by purpose, integrity, and impact.
Where knowledge meets innovation, new futures unfold...
At a glance
Scientific Contributions
Over 20 years of published research in α-synuclein biology and biomarker development form the backbone of QABY’s diagnostic and therapeutic programs.
Global Engagement
Active participation in international collaborations, scientific networks, and synucleinopathy research initiatives.